December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
SWS-Cone-Mediated Sensitivity and Tamoxifen Use
Author Affiliations & Notes
  • A Eisner
    Neurological Sci Inst Oregon Hlth Sci Univ Beaverton OR
  • SN Burke
    Neurological Sci Inst Oregon Hlth Sci Univ Beaverton OR
  • DF Austin
    Public Health & Preventive Medicine
    Oregon Hlth Sci Univ Portland OR
  • AT Evans
    Neurological Sci Inst Oregon Hlth Sci Univ Beaverton OR
  • JR Samples
    Casey Eye Inst
    Oregon Hlth Sci Univ Portland OR
  • Footnotes
    Commercial Relationships   A. Eisner, None; S.N. Burke, None; D.F. Austin, None; A.T. Evans, None; J.R. Samples, None. Grant Identification: EY12737, CA69533
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 2953. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A Eisner, SN Burke, DF Austin, AT Evans, JR Samples; SWS-Cone-Mediated Sensitivity and Tamoxifen Use . Invest. Ophthalmol. Vis. Sci. 2002;43(13):2953.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: This research follows from reports that age-related changes of SWS-cone mediated vision are gender-dependent, and from reports that the retina contains estrogen receptors. This research aims to determine whether tamoxifen, a selective estrogen receptor modulator used as adjuvant treatment for estrogen-receptor-positive breast cancer, can affect SWS-cone-mediated sensitivity. Methods: SWS-cone-mediated sensitivity was measured in 2 ways: 1) across the visual field of each eye using Short-Wavelength-Automated Perimetry (SWAP), and 2) in the fovea of one eye using psychophysical increment-threshold techniques to assess changes in SWS-cone mediated sensitivity as a function of time after onset of a bright (3.6 log td) yellow (580-nm) background. A total of 51 women were tested. All used 20 mg tamoxifen daily subsequent to primary treatment for breast cancer, and all had acuity of at least 20/20 in the eye tested foveally and 20/25 in the fellow eye. Results: The SWAP mean-deviation was ≷ 0 in each eye for 10 of the 11 subjects who used tamoxifen < 10 months. In other words, the sensitivity averaged across the visual field and corrected for age exceeded the normal mean for 10 of 11 subjects. From 1-3 years, tamoxifen users separated into 2 subgroups according to whether their mean-deviations were high or low. The mean-deviations of only 2 of 23 subjects were within + 2 dB of 0, whereas the mean-deviations of 11 and 10 subjects were ≷ 2 dB or < -2 dB, respectively. There was no eye-dependent ambiguity. The sensitivities of the low-mean-deviation subjects decreased more at far eccentricities (15- 21) than at near (< 3), as compared with the corresponding difference for high-mean-deviation subjects (p=.014 for eye 1 and p=.034 for eye 2, Mann Whitney U tests). By 4 years or more, 4 of 6 subjects had mean-deviations within + 2 dB of 0 for at least 1 eye. In the fovea, there was no apparent separation into subgroups. The degree of desensitization shortly (20-30 seconds) after onset of the yellow background was correlated (ρ =.47, p=.002) with duration of tamoxifen use, as determined using a multilinear regression model that included age. Conclusion: Tamoxifen affects SWS-cone-mediated sensitivity progressively over a period of years. At the fovea, visual adaptation is altered. This suggests a retinal locus of activity, perhaps involving estrogen receptors. The separation of tamoxifen users into 2 subgroups may potentially have implications for identifying breast cancer patients who are most likely to benefit from a standard 5-year course of tamoxifen treatment.

Keywords: 353 clinical (human) or epidemiologic studies: outcomes/complications • 624 visual fields • 384 dark/light adaptation 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.